Physician profile
Peter Arreguin
NPI 1265916704
$524.24
in general payments reported to CMS, 2019-2025
11 companies · $89.02 in 2025
The $89.02 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.07 · 2022: $51.72 · 2023: $136 · 2024: $226 · 2025: $89.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $106.29 | 2022-2024 | |
| Genentech USA, INC. | $75.55 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Alexion Pharmaceuticals, INC. | $66.30 | 2021-2023 | Ultomiris |
| Abbvie INC. | $55.93 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.36 | 2025 | Hyqvia |
| Astrazeneca Pharmaceuticals LP | $40.80 | 2023 | |
| Ucb, INC. | $36.64 | 2024 | Cimzia |
| Glaxosmithkline, LLC. | $34.16 | 2022-2025 | Nucala |
| Amgen INC. | $23.67 | 2023 | Prolia, Evenity |
| Lilly USA, LLC | $21.40 | 2024 | Omvoh |
| Amag Pharmaceuticals, INC. | $18.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Arreguin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.